| Name | Title | Contact Details |
|---|
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our strength lies in our exclusive focus and singular influence on the worldwide effort to end T1D.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
Heart To Heart Medical Ctr is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Phoenix Translations is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lansinoh Laboratories Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Alexandria, VA. To find more information about Lansinoh Laboratories Inc, please visit www.lansinoh.com